← Human Trials & Peer-Reviewed Studies
Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes.
Plain-language guide to PMID 23298824 (2013): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in 100 patients.
Key Facts
- PMID
- 23298824
- Journal
- Atherosclerosis
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Yiu YF et al. (12 authors)
- DOI
- 10.1016/j.atherosclerosis.2012.12.013
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).
The aim was to investigate the effect of vitamin D supplementation on endothelial function in patients with type 2 diabetes mellitus (DM).
Who Took Part
The abstract describes 100 patients taking part.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Assessment of vascular function with brachial artery flow-mediated dilatation (FMD), circulating levels of endothelial progenitor cells (EPCs) and brachial-ankle pulse wave velocity, and metabolic parameter, high-sensitivity C-reactive protein (hsCRP) and oxidative stress markers were performed before and after the supplementation.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
What Was Measured
The subject headings attached to it are Biomarkers, Brachial Artery, C-Reactive Protein, Calcium, Cholecalciferol, Diabetes Mellitus, Type 2 and Endothelium, Vascular.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in 100 patients.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2013 (Atherosclerosis), a journal based in Ireland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.
Our Notes on the Compounds
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.